Meneveau et al. designed and evaluated an open-label, randomized phase I study of a transdermal vaccine comprising a mixture of twelve MHC class I-restricted melanoma peptides (originating from antigens of tyrosinase, gp100, MAGE-A1, MAGE-A3, MAGE-A10, and NY-ESO-1), a tetanus helper peptide (tet; AQYIKANSKFIGITEL), and GM-CSF. The gene discussed is CSF2; the disease is melanoma.